Development of a Risk Model Predicting Chemotherapy-induced Grade 3-4 Neutropenia by Paclitaxel/Carboplatin in Epithelial Ovarian Cancer: Prospective Observational Study for Model Development and Retrospective Study for Validation of Developed Model
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Pharmacogenomic
- 31 May 2017 Biomarkers information updated
- 17 Sep 2012 New trial record